What happened with PASG today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Passage Bio is developing treatments rather than selling medicines: it has no approved products and has not generated commercial product revenue. Its only clinical-stage candidate, PBFT02, is being tested in patients with frontotemporal dementia linked to GRN mutations. Future drug sales depend on successful development and regulatory approval; U.S. approval would not permit sales in other countries without separate local approvals.
Gemma pays Passage Bio for rights to its outlicensed pediatric drug programs, along with transferred trial materials, regulatory dossiers and product supply. The agreements also provide for potential milestone payments and royalties if Gemma advances the programs and sells the resulting medicines. Those downstream payments depend on Gemma continuing development and commercialization.
Passage Bio also relies on Gemma for much of its early research and on Catalent to manufacture clinical supplies. Its licensed drug rights are limited to specified indications and depend on meeting contractual obligations. Until substantial product revenue arrives, it expects to fund operations through financing and partnerships, with no committed external funding source.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Passage Bio’s prospects hinge on PBFT02’s clinical progress against its closest rival, privately held AviadoBio, alongside manufacturing execution and continued financing.
Denali Therapeutics Inc. competes with Passage Bio’s PBFT02 to treat patients with GRN-associated frontotemporal dementia, using a manufactured progranulin protein rather than gene therapy. Watch its Phase 1/2 trial with Takeda for efficacy and safety results that could change PBFT02’s competitive position.
Voyager Therapeutics, Inc. competes with Passage Bio in gene therapies targeting MSH3 for Huntington’s disease; both programs are preclinical. Progress in Voyager’s MSH3 program is the comparison to watch as Passage Bio aims to name a clinical candidate in the second half of 2026.
Taysha Gene Therapies, Inc. offers a safety and regulatory comparison for Passage Bio: both use adeno-associated viruses (AAV) to deliver genetic material to central nervous system cells, but treat different diseases. Watch whether Taysha’s Rett syndrome treatment TSHA-102 maintains safe gene expression, a central issue for this approach.
REGENXBIO Inc.’s progress in delivering and manufacturing AAV gene therapies for neurodegenerative lysosomal diseases provides a reference for Passage Bio’s own AAV programs. Its RGX-121 for MPS II and RGX-111 for MPS I are the programs to follow; REGENXBIO also funds its research by licensing its gene-delivery vectors to other drug developers.
Sarepta Therapeutics,, Inc.’s marketed AAV therapy ELEVIDYS provides a safety and regulatory reference for Passage Bio’s investigational AAV therapies, not a direct treatment rival. In November 2025, Sarepta announced a boxed warning for acute liver injury and acute liver failure and removed non-ambulatory Duchenne patients from the U.S. indication—restrictions to watch when assessing AAV safety scrutiny.
Taysha Gene Therapies, Inc. earningsTSHA
Taysha Gene Therapies’ report will show how its Rett syndrome AAV therapy is progressing on safety and development, giving Passage Bio a reference point for risks facing its own central nervous system gene therapies.
Watch what Taysha says about TSHA-102’s safety and continued development; the stated concern is whether the treatment can maintain safe gene expression. Progress with reassuring safety information would support continued work on this approach in another central nervous system disease. Safety concerns or development limits would highlight risks relevant to Passage Bio’s AAV programs, though the companies treat different diseases and their results are not interchangeable.
Denali Therapeutics Inc. earningsDNLI
Denali Therapeutics’ report will show what its Takeda-partnered trial for GRN-associated frontotemporal dementia has found, providing a direct competitive reference for Passage Bio’s PBFT02.
Watch whether Denali and Takeda report efficacy and safety findings from their Phase 1/2 trial. Evidence supporting the progranulin-protein approach for GRN-associated frontotemporal dementia would make it a stronger alternative competing for the same patients; weak findings or safety problems would ease that specific competitive pressure, but would not show that PBFT02 works.
Passage Bio, Inc. earningsThis company
Passage Bio has no approved products to sell, so cash funds its research; this report will show whether the cost of advancing the PBFT02 trial remains in line with its available funds.
Read operating cash used alongside the cash balance, and watch how research spending changes. Slower cash use while the PBFT02 trial advances would leave more time to fund the lead program; faster cash use would shorten that time and increase pressure to raise money or slow development.
